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Research suggests that specific compositions of gut microbiota can
directly affect energy harvesting and fat storage, which may indicate a potential
role of intestinal bacteria in the regulation of body weight (i.e., obesity). The
purpose of the current study was to determine if prebiotic- and probiotic-based
diets modify gut microbiota in genetically obese rodents. For this, female Zucker
diabetic fatty (ZDF) rats were assigned diets containing fructooligosaccharides
(FOS), Bifidobacterium (BIF), or Lactobacillus (LAC) for three weeks. qPCR was
then used to measure levels of colonic Bifidobacterium, Lactobacillus, and total
bacteria. At termination, there was no significant difference in Lactobacillus levels
between diets. However, there was significantly less Bifidobacterium in BIF vs.
FOS or LAC-fed rats. The evidence in this study shows there were no significant
differences in Lactobacillus levels between any of the feeding groups and the
control group, supporting the conclusion that ingestion of any of the tested
supplemented food does not statistically modulate Lactobacillus numbers in
female ZDF rats. However, the rats from the Bifidobacterium and FOS feeding
groups had significantly higher colonic Bifidobacterium levels than the control
group from ingesting the supplemented food, indicating that the presence of the
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probiotic Bifidobacterium animalis subspecies lactis and the prebiotic FOS
stimulated the growth of Bifidobacterium.
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CHAPTER 1
INTRODUCTION
Obesity and Type 2 diabetes mellitus (T2DM) are at epidemic
proportions, with obesity rates increasing markedly over the past three decades.
According to the Centers for Disease Control Behavioral Risk Factor Surveillance
System, there was no state with obesity prevalence ≥15% in 1990. However, in
just over 20 years this rate increased to ≥30% in several states.1
Obesity results from an imbalance in energy intake and expenditure.
Furthermore, obesity is linked to a variety of comorbidities, such as T2DM.
Currently, >8% of Americans are diagnosed with T2DM, whereas an additional
27% are thought to be undiagnosed.2 It is also estimated that approximately one
in 400 people under 20 years of age in the U.S. have diabetes (type 1 or type 2).2
The underlying factor contributing to increasing prevalence of T2DM is the
corresponding rise in obesity rates.
Probiotics are classified as live nonpathogenic microorganisms, such as
bacteria or yeast, which confer physiological health benefits through changes in
the host gut microbiota.3-5 Alternatively, prebiotics are selectively fermented
ingredients (i.e., dietary fiber) that allow specific changes in the composition
and/or activity of gut microbiota that also results in multiple health benefits for the
host.6 However, not all dietary fibers are be considered prebiotic, as some
stimulate potentially harmful bacterial growth or metabolism, and thus are not
selective to beneficial bacteria.7 A plethora of research has investigated the
positive effects of prebiotics and probiotics in humans. However, more recent
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data has indicated that changes in gut microbiota through consumption of
probiotics and prebiotics may influence the progression of obesity and its related
comorbidities through modifications to energy harvesting and fat storage in
hosts.8-11
Statement of the problem. Preliminary research investigated the
potential metabolic effects of prebiotic and probiotic based diets on genetically
obese Zucker diabetic fatty (ZDF) rats.12 However, this previous work did not
measure the bacteria profiles in obese and diabetic rats.
Purposes of the study. The primary purpose of this study was to
determine how consumption of prebiotics and probiotics modified gut microbiota
in obese ZDF rats. Additionally, another purpose was to describe the bacterial
profile in these animals associated with metabolic outcomes (i.e., hyperglycemia,
adiposity, etc.).
Research questions. 1. Can we detect if probiotics or prebiotics made a
significant difference in the number of microorganisms in the gut? 2. And, within
those differences can we determine if we are selecting for either of the two
genera we were measuring using q-PCR?
Statement of hypothesis. We hypothesized that the prebiotics and
probiotics would increase intestinal microflora and that we would select for both
genera. We also hypothesized that the bacterial changes would correlate with
positive metabolic outcomes.
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CHAPTER 2
REVIEW OF THE LITERATURE
Obesity and T2DM are at epidemic proportions, with prevalence of each
exhibiting a marked increase over the past three decades. Among the states that
participated in the Centers for Disease Control Behavioral Risk Factor
Surveillance System in 1990, 10 had prevalence of obesity less than 10% and no
state had prevalence ≥15%. By 2000, no state had prevalence of obesity less
than 10%, 23 states had a prevalence of 20–24%, and no state had a prevalence
of ≥25%. However by 2010, no state had an obesity prevalence of less than 20%
and 36 states had ≥25% with 12 of those having ≥30% prevalence (Figure 1). In
2012, no state had a prevalence of obesity less than 20%, nine states and the
District of Columbia had a prevalence of between 20–24%, and 13 states had a
prevalence ≥30%.1 Obesity increases the risk of many health conditions,
including coronary heart disease, stroke, hypertension, and cancers (i.e.,
endometrial, breast, and colon).13
Obesity results from increased intakes of energy-dense foods and
decreased physical activity. However, when an entire population is exposed to
the same nutritional stresses, certain individuals within that population do not
experience similar weight gain and metabolic dysfunction. This suggests that
there are additional mechanisms beyond energy intake and expenditure.8
Type 2 diabetes mellitus (T2DM) results in the body’s inefficient use of
insulin. In 2011, T2DM affected over eight percent of Americans with an
additional 27% still undiagnosed.14 About 3,600 people under 20 years of age in
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the U.S. are newly diagnosed with T2DM every year.14 T2DM is largely caused
from excess body weight and a lack of physical activity.15
Much research has been conducted over the years regarding the effects
of prebiotics and probiotics in the diet. More recently, research has demonstrated
that specific compositions of gut microbiota can directly affect energy harvesting
and fat storage. These data indicate that prebiotics/probiotics may distinctly
impact pathophysiology of obesity.8-11
Introduction to probiotics
A diverse and complex gut microbial ecosystem exists that is
indispensable for the human host’s health and wellbeing, even beyond the
gastrointestinal tract. This environment is sterile in infancy, develops through
childhood, matures in adulthood, and becomes more complex in old age. It is
stable, but ever changing. Consequently, the “normal flora” is able to perform
mechanistic roles that the human body cannot do itself.16
Modern definitions. The World Health Organization (WHO) defines
probiotics as live microorganisms which when administered in adequate amounts
confer a health benefit on the host.3 Another source affirms a probiotic to be a
live microorganism that is administered to alter the intestinal microflora, thereby
conferring a beneficial effect on the patient’s health.4 And another more recently
states that probiotics are viable, nonpathogenic microorganisms (bacteria or
yeast) that are able to reach the intestines in sufficient numbers to confer benefit
to the host.17 An integrated definition of probiotics is live, nonpathogenic
microorganisms (bacteria or yeast) which when administered in adequate
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amounts and which reach the intestines in sufficient numbers confer a beneficial
effect on the health of the host.
Microbial ecology of the GI tract
Each person has a unique and stable gut microbial environment, but
community shifts do occur. Age, gender, diet, health, and medications
(antibiotics, in particular) can cause variations in the general blueprint associated
with the human GI tract.18 About 3.3 million genes constitute the gut microbiome,
about 150 times larger than the number of genes identified in the entire human
genome. It is believed that up to 100 trillion microorganisms consisting of over
1000 species inhabit the individual adult intestine at any given time,18,19 which is
10X the number of cells in the human body.16 More recently, a study based on
over 50,000 16S rRNA gene sequences distinguished about 1800 genera,
16,000 species, and over 36,000 strains of bacteria overall in the human
intestine.10
Four bacterial groups comprise 98% of the total human gut microbiome:
Actinobacteria (3%), Proteobacteria (8%), Bacteroidetes (23%), and Firmicutes
(64%).10 The latter group constitutes the largest percentage and contains within it
two genera of interest to this research, Bifidobacterium and lactic acid bacteria of
the genus Lactobacillus. They are considered “normal flora” of the
gastrointestinal tract.
The acidic pH of the stomach prevents growth of most bacterial species.
Only about 103 g-1 of intestinal contents survive this harsh environment and those
that do are found predominantly on the walls of the stomach.20,21 These are
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primarily Gram-positive facultatively anaerobic genera such as Lactobacillus,21
though a few aerobic and Gram-negative bacteria can be found as well (Figure
2).
Bacterial concentration in the small intestine is typically between 104 and
108 g-1 contents and primarily consists of some facultative anaerobes and some
strict anaerobes. The number of commensal bacteria in the small intestine is still
limited by the low pH from stomach acid.17 The pH of the duodenum is 6–6.5, but
the area in and around the brush border can reach 7–8.22 In the proximal small
intestine (i.e., duodenum and jejunum) Lactobacillus and Enterococcus
predominate with bacterial concentration ranges from 104 and 105 g-1.10,20 In the
distal small intestine (i.e., ileum), the bacterial composition begins to resemble
the large intestine, which includes the following genera: Bacteroides, Clostridium,
Eubacterium, Peptostreptococcus, Ruminococcus, Fusobacterium, Butyrovibrio,
Enterobacterium, Lactobacillus, and Bifidobacterium.4 However relatively
speaking, numbers of Lactobacillus drop 20 and gram-negative bacteria far
outnumber gram-positive bacteria in the distal small intestine.4 The pH in the
jejunum and ileum is about 7.5.22
The microflora of the colon is one of the most densely populated microbial
habitats known, around 1011 to 1012 g-1 contents 4,17,18,23 and is quite diverse
consisting of at least 500 microbial species.17 Bacteria make up about 60% of the
mass of human fecal matter,17 dominated by the genera Bacteroides,
Eubacterium, Fusobacterium, Butyrovibrio, Peptostretococcus, Clostridium,
Fusobacterium, Ruminococcus, Lactobacillus, and Bifidobacterium.4,24 The large
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intestine contains much larger numbers of obligate anaerobes than facultative
anaerobes.25
Species of the genera Eubacterium, Lactobacillus, and Bifidobacterium
are typically used as probiotics in many dietary supplements and functional foods
on the market today.18,26 These probiotics function to out-compete pathogenic
bacteria such as Staphylococcus, Clostridium, and Pseudomonas. Two of these
probiotic bacteria, Lactobacillus and Bifidobacterium, are the most commonly
studied probiotic genera in the literature, selected based on their consistently
viable, safe, and metabolically active characteristics.
Health benefits of probiotic use
Modern humans are considerably less exposed to microbes than our
ancient ancestors with the modern Western diet consisting of much less fiber,
non-digestible carbohydrates, and whole plant foods (fruits, vegetables, whole
grains) and much more protein, saturated fat, and refined sugar. Such health
issues as allergic and inflammatory maladies, metabolic syndrome (including
obesity, hypertension, dyslipidemia, glucose intolerance, and insulin resistance),
cancer, diabetes, stroke, and cardiovascular disease 27-29 are prevalent in
modern Western society. Many studies have focused on beneficial health effects
attributed to gut microbes’ symbiotic influence.
Improvement of bowel function. A notable benefit is the improvement of
bowel habits. Irritable bowel syndrome (IBS),28,30 diarrhea (particularly antibioticassociated),17,31 and ulcerative colitis 31,32 are among the most common gut
problems studied with probiotic consumption.
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Good bowel function relies heavily upon short-chain fatty acid (SCFA)
formation. From the breakdown of unabsorbed carbohydrates, several species of
Eubacterium and other Firmicutes produce the SCFA butyrate, a major source of
nutrition for colonocytes.31,33 SCFAs have a positive effect on processes such as
carcinogenesis and gene expression, energy metabolism, and cholesterol and
lipid levels.29 Diets deficient in dietary fiber have decreased production/
concentration of fecal SCFAs34; however, it was observed that humans who
consumed a restricted carbohydrate diet with probiotics maintained SCFA
production.35 Furthermore, after the administration of probiotic supplements for
six months, the microbiota associated with IBS patients changed toward that of
IBS-free patients.30
The symptoms of acute diarrhea have been improved with probiotics by
21% and that of antibiotic-associated diarrhea improved by 52%.5 Lactobacillus
have been particularly effective for improving the symptoms off chronic
diarrhea.31 In eight of ten randomized controlled trials, it was reported that a
significant number of participants experienced improvement from antibioticassociated diarrhea using the probiotic yeast Saccharomyces boulardii.36 Many
GI disorders are treated with broad-spectrum antibiotics that actually exacerbate
the disease with osmotic diarrhea and diarrhea associated with opportunistic
and/or antibiotic resistant pathogenic bacteria, such as Clostridium difficile and C.
perfringes, Salmonella, Staphylococcus aureus, or Proteus. As such, probiotic
therapy can be used to quickly re-establish the normal flora and provide effective
competition against pathogens.10,37-39

8

`
In patients with ulcerative colitis (UC), probiotics have been shown to
relieve symptoms.31 Fecal samples from UC patients can contain very high
concentrations of lactate.33 Some bacteria, including species of Eubacterium and
Bifidobacterium, are able to ferment lactate to butyrate and this could explain
how those without UC remove lactate from the colon.33 However, there are other
colonic bacteria that also can produce butyrate, so the evidence for probiotics is
still unclear in UC cases.
Immune system benefits. The gut-associated lymphoid tissue (GALT) is a
substantial component of the body’s immune system. Research has discovered
that probiotics modulate the intestinal immune response18 and help to combat
allergies.35,40 For example, Lactobacillus salivarius and other probiotics positively
influence Natural Killer cells and monocytes. These leukocytes affect both the
innate and specific immune responses.31,35
Certain strains of Lactobacillus clearly play a role in the development and
function of dendritic cells [special cells for presenting antigens to T helper cells
(cells which signal immune responses)].41,42 The majority of dendritic cells in the
GI tract are immature, and are subject to maturity based on their environment.41
Mature dendritic cells produce the cytokine IL-12, which is important in
differentiation of TH1 subset helper T cells.41,42
Reduced intestinal permeability. The main entry points for most
pathogenic bacteria are on luminal mucous membrane surfaces.20 Secretory
Immunoglobulin A (sIgA) binds antigens on pathogens, entrapping them within a
hydrophilic shell and preventing them from attaching to mucosal cells and
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colonizing the colon.17,42 Probiotics have been shown to raise sIgA levels in the
luminal mucous layer.17
Once in the gastrointestinal tract, lactic acid bacteria produce bacteriocins,
bacteriocidal (killing), or bacteriostatic (growth inhibiting) peptides.5,43
Bacteriocins destroy gram-negative bacteria by penetrating the inner membrane
or interrupting cell wall synthesis.5 Bacteriocins are promising as future
antimicrobial agents because thus far there have been no side effects or
resistance reported with their use.43 Additionally, due to the fact that they are
proteins, which are easily degraded.43
Probiotic bacteria such as Lactobacillus and Bifidobacterium produce
SCFAs by fermenting 80–90% of the carbohydrates that the human host cannot
digest (i.e., dietary fiber).18,31 The production of both SCFAs and high levels of
lactic acid by lactic acid bacteria creates conditions detrimental to the pHsensitive cytoplasmic membrane of pathogenic bacteria (e.g., C. perfringens) and
this causes the cells to lyse.10,20 SCFAs are beneficial to the host metabolism by
increasing intestinal motility, absorption, defecation frequency, lipid and
carbohydrate metabolism, mucus production, and blood flow to the large
intestine.35,44,45
Obesity link. A more recent hypothesis relates to the connection of obesity
with the microbial composition of the gut. In mice, a mutation in the leptin (ob)
gene causes deficiency of the adipose-regulating hormone leptin and is linked
with early-onset obesity.46 The gut microbial community of genetically obese
(ob/ob) mice contains 50% fewer Bacteroidetes species and 50% more
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Firmicutes than their lean wild-type (+/+) littermates.9,11 Furthermore, the
intestinal microbiota of obese mice is less diversified and contained a greater
number of methanogens (Archaea that produce methane).10
When feces of genetically obese mice was measured by bomb
calorimetry, results disclosed substantially less energy than their wild-type
siblings (Figure 3a).9 The proposed mechanism is that members of the
Firmicutes convert more dietary fiber to short chain fatty acids, hence the host
animal gets more fat from the same amount of food.10 Within two weeks, the
germ-free mice experienced a significant increase in adiposity despite equal or
decreased food quantity, indicating that obesity is transmissible (Figure 3b).9,11
The conclusion is that the microbiota regulate the host’s harvest of energy and
organic nutrients from the diet.
In a study with human subjects, a similar Bacteroidetes/Firmicutes
relationship was found regardless which diet the subjects were on (fat-restricted
vs. carbohydrate-restricted). Interestingly, this correlation remained consistent
following significant weight loss (Figure 4).11 Moreover, there was a significant
correlation between the increase of Bacteroidetes and weight loss percentage
(Figure 5).11
As mentioned previously, methanogens are more abundant in the gut of
ob/ob mice. Methanogens remove the products of fermentation from the gut, in
particular, acetate, hydrogen (H2), and carbon dioxide (CO2). The removal of H2
from the gut in the reduction of CO2 to methane makes the energetics of
fermentation more favorable. This in turn, makes available additional nutrients for
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the host to absorb, contributing to obesity.10 This has imminent therapeutic
implications for the treatment of obesity.9
More benefits of SCFAs. In addition to providing energy for colonocytes
and lowering the pH of the colon to maintain the integrity of the mucosa, there
are several other positive functions from the breakdown of nondigestible
carbohydrates to SCFAs by probiotic bacteria. A summary of some of the
benefits of probiotics, many well studied as well as others in earlier research
stages, are listed in Table 1.
Prebiotics
Prebiotics are nondigestible food ingredients that beneficially affect the
host by selectively stimulating the growth and/or activity of one or a limited
number of bacterial species already resident in the colon.7 This definition has
more recently been updated to selectively fermented ingredients that allow
specific changes. Both in the composition and/or activity in the gastrointestinal
microbiota confer benefits upon host well-being and health.6 Consequently, not
all dietary fibers can be considered prebiotic, as some dietary fibers stimulate
potentially harmful bacterial growth and/or metabolism, and so are not selective
to beneficial bacteria.7
Humans lack the opacity to digest dietary fiber. As such, enteric microflora
to catabolize them.47 When lactic acid bacteria (primarily Bifidobacterium)
ferment fiber, the pH of the large intestine is reduced.20 Therefore, the growth of
bacteria that are already resident in the colon can be accelerated with the use of
prebiotics, which provides an advantage over simple probiotic usage.6,48
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Interestingly, prebiotics possess differing fermentation profiles, so some
metabolites can be converted or used as substrates for other prebiotics — this is
called “metabolic cross-feeding”.49 Typically, the competition will positively affect
those groups that are considered to be healthy for the host47 and negatively
affect unfavorable bacteria.49-51 A prime example is by the anaerobic gut bacteria
converting lactate produced by Bifidobacterium into butyrate and other SCFAs.48
A requirement to be considered a prebiotic is that it must reach the colon
as a fermentable substrate, meaning it has to be at least partially unhydrolyzed
and unabsorbed in the small intestine.50-52 Prebiotics do not replace the normal
flora but spur growth of the lactic acid bacteria such as Bifidobacterium and
Lactobacillus, or activate them metabolically, or both. Thus, the colonic microbial
composition is shifted by prebiotic consumption.47,51
Specific prebiotics. Dietary fiber such as cellulose, lactosucrose,
polydextrose, indigestible dextrin, soy polysaccharide, rice bran, and chitosan
can alter the microbiota.4 In this country, the fructans are the most common
prebiotic additive used in food.28 This group includes oligosaccharides such as
galactooligosaccharides, lactulose,18 and short-chain fructooligosaccharides
(synonymous with oligofructose) found in garlic, artichokes, onions, bananas,
tomato, leeks, and wheat.28 Additionally, they are manufactured from sucrose or
extracted from chicory.28,52,53 Xylooligosaccharides, isomaltooligosaccharides,
and soybean oligosaccharides have all been touted as having prebiotic qualities,
however more research is needed to bump them from their classification of
tentative prebiotics to established prebiotics.52
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Synbiotics
Synbiotics are probiotics in the form of live microorganisms and certain
prebiotics available in the same product concurrently.18,44,50 Synbiotics increase
the likelihood that the probiotics survive and thrive since a preferred substrate,
the prebiotic, is easily accessible.51
The different segments of the intestine have disparate substrate
concentrations and pH levels. A study of several combinations of probiotics and
prebiotics found an optimum combination with a strain of Lactobacillus
acidophilus with mannitol, fructooligosaccharides, and inulin.44 A list of examples
of common probiotics, prebiotics, and synbiotics can be found in Table 2.
There are so many probiotic products on the market, it is difficult for
consumers to know what to purchase. There are many varieties with regards to
formulations, stability, and quality control, as well as the problem of matching the
appropriate probiotic with the disease or condition experienced by the patient,
much less when prebiotics are added to the mix (synbiotics).
Recommended dosages of prebiotics vary depending on the type of
prebiotics consumed. Differing ranges of dosages are the result of the variable
fermentation characteristics of the prebiotics.28 Package labels with terms such
as starch, corn starch, modified food starch, and maltodextrin are indicators of
resistant fiber, but not all are resistant to digestion, so the savvy consumer still
must consult the actual fiber content on the nutritional label.28
Typical carbohydrates of the human diet consist of resistant starch, nonstarch polysaccharides, such as cellulose, hemicellulose, inulin, and pectin, non-
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absorbable sugars and sugar alcohols, and chitin and amino sugars — none of
which are well fermented by Lactobacillus.20 They may instead rely on the
hydrolytic activity of bacteria such as Bifidobacterium and Bacteroides for their
carbohydrates.20 However, they can ferment prebiotic carbohydrates such as
galactosaccharides, fructooligosaccharides, raffinose, stachyose, lactitol, and
palatinose.54
Preliminary studies
The original feeding study on which this thesis is based was conducted by
Michele Martin under the direction of Dr. D. Allan Higginbotham with the purpose
of determining anti-obesity and anti-diabetic effects of prebiotics and probiotics
added to soy protein diets in the female Zucker diabetic fatty or ZDF-Leprfa/Crl
(ZDF) rat model.12 The ZDF emanates from the inbreeding of hyperglycemic
Zucker obese rats.
Male ZDF rats have an fa gene mutation in which the leptin receptor
protein does not interact with leptin (the cytokine product of the ob gene which
increases energy expenditure and decreases food intake, thus lowering body
weight).55,56 This results in constant messages of hunger being sent out by the
hypothalamus, and continuous eating ensues.57
When put on a regular (Purina 5008, 16.7% kcal fat) diet the obese female
ZDF rats will gain weight but remain euglycemic and will not develop diabetes. 58
Female ZDF rats were used in the preliminary study because when subjected to
a high fat diet (27% fat was used in the preliminary feeding study), they develop
Type 2 Diabetes Mellitus.12
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The hypothesis was that the prebiotics and probiotics would affect
intestinal microflora and maximize the anti-obesity and anti-diabetic effect of the
soy protein. The research questions were whether FOS, B. animalis subsp.
lactis, or L. acidophilus in a soy-based diet decrease body weight and fat gain,
and improve glycemic control in a preclinical model of T2DM. These strains were
chosen as they have been well studied for their biological action and potential
applications for commercial probiotic supplements.
A soy-based protein diet was chosen based on evidence that it could
improve glycemic control.12 Intestinal microflora may modify undigested soy
protein components (possibly the isoflavones), and could be a method to improve
glycemic control and prevent weight gain. Soy isoflavones affect glucose and
triglyceride metabolism, which in turn, affect insulin levels.12 Soy polysaccharides
can improve glucose tolerance by reducing glucose and triacylglycerol
concentrations.12
A 60-day study using rabbits as their animal model found that daily
ingestion of a probiotic (Enterococcus faecium and Lactobacillus helveticus) soy
product resulted in significant increases in fecal Lactobacillus and
Bifidobacterium species counts compared to the control group. The unfermented
soy food did not increase those bacterial populations. The experimental group
also was found to have a reduced risk of cardiovascular disease.59
Many different animal models have been used to study probiotics,
including human. Important data can be gleaned using tissues from an animal
host that would not be accessible from human models. By using rats in this
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experiment, the entire colon could be extracted in order to take into account
intestinal adhesion across the epithelium common with some strains of probiotic
bacteria. Other tissues were taken from these experimental rats for the
preliminary study.12 Even if the dosages/specific organisms used are not
realistic/appropriate for human comparisons, we can potentially obtain relevant
results from animal experiments suitable for advancing our understanding of the
use and activity of probiotics in humans.
This study aimed to determine changes in Lactobacillus, Bifidobacterium,
and total bacteria in the colon and feces of rats fed conventional, prebiotic, and
probiotic soy-based diets using these obese diabetic rats. The research
questions are: can we detect if probiotics or prebiotics made a significant
difference in the number of microorganisms in the gut; and, within those
differences, can we determine if we are selected for either of the two study
genera using q-PCR?
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CHAPTER 3
MATERIALS AND METHODS
Animals and Diet. Twenty-four female obese Zucker Diabetic Fatty rats
(ZDF-Leprfa/Crl; Charles River Laboratories, Raleigh) were block randomized by
body weight to control or experimental diets (n=6) (Table 3). All diets were
isocaloric and isonitrogenous with 50% of total kcal from fat. Experimental diets
were supplemented with 2.5% of fructooligosaccharide (FOS), Bifidobacterium
animalis (BIF), or Lactobacillus acidophilus (LAC). Animals were housed in the
Southern Illinois University Carbondale Vivarium under the supervision of the
Institutional Animal Care and Use Committee (IACUC). Rooms were temperature
controlled and light regulated, and rats were housed in individual wire cages.
Food was measured daily and rats were weighed three times per week.12
All diets contained 27% fat. The control soy diet was comprised of 42.9%
carbohydrate and 17.9% starch while the FOS, Bifidobacterium, and
Lactobacillus soy diets all consisted of 40.4% carbohydrate, 25% sucrose, 15.4%
starch, and 2.5% functional (see Table 3 for complete composition of
experimental diets).
Sample Collection. The feeding study was conducted for three weeks
until rats exhibited severe hypoglycemia with lesions. Rats were euthanized and
tissue samples collected. A colon sample was also removed from each rat,
placed in a sterile conical tube, and immediately immersed in liquid nitrogen until
samples were placed in an ultra-cold (-80°C) freezer.
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Bacterial acquisition, growth conditions, and isolation. Bacterial
control strains were obtained from the SIUC Department of Microbiology’s stock
culture collection and were grown under semi-aerobic conditions overnight in
10 ml screw-capped tubes partially filled with Bacto Tryptic Soy (TS) broth at
37°C. These strains were used as controls for primer optimization (Table 4).
Two strains intended for use in this research, Lactobacillus acidophilus
(NRRL B-4495) and Bifidobacterium animalis (NRRL B-41405) were obtained
from the culture collection of Dr. Alejandro P. Rooney at the U.S. Department of
Agriculture’s National Center for Agricultural Utilization Research in Peoria,
Illinois. Due to problems growing a sterile B. animalis culture, B. infantis was later
acquired from Chr. Hansen, Inc. (I-Powder-50; Milwaukee). The taxonomic
descriptions of the genera Lactobacillus and Bifidobacterium are shown in
Appendix A.
Probiotic strains were grown aerobically overnight in MRS broth in partially
filled 10 ml screw-capped tubes or on agar plates in BBL Gas-Pak™ jars (Becton
Dickinson, Sparks, MD) at 37˚C. The MRS medium (containing trypticase soy
powder, dextrose, beef brain heart infusion, peptone, sodium acetate, yeast
extract, sodium citrate tribasic dihydrate, sodium phosphate dibasic anhydrous,
polysorbate (Tween) 80, magnesium sulfate heptahydrate, manganese sulfate
tetrahydrate, thiosulfate, L-cysteine hydrochloride, MOPS, and cobalamin) was
adjusted to pH 6.5 ± 0.2 at room temperature, brought to volume, and gently
heated to boiling. Medium was then added to loosely capped 10 ml screw-
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capped tubes and autoclaved at 121°C for 20 min. For culture plates, Bacto™
agar was added to the medium prior to the boiling step.
Quantitative PCR. To optimize primers, relative quantification of bacterial
DNA in samples was determined using quantitative real-time PCR (qPCR), which
is 10–100 times more sensitive than the plate-count method.60 Pure cultures of
all bacterial control and study strains were harvested from a centrifuged bacterial
pellet from 10 ml of culture and subsequently isolated using the E.Z.N.A.™
Bacterial DNA Isolation Kit (D3350, Omega Bio-tek, Inc., Norcross, GE)
according to manufacturer’s instructions.
Comparison tests were performed to evaluate primers sets for optimum
determination of relative Bifidobacterium, Lactobacillus, and total bacteria
concentration in colon samples (Appendix B). The 16S gBifid, 16S Lact, and 16s
p338fGC/P518R primer sets were used for measurement of Bifidobacterium,
Lactobacillus, and total bacteria, respectively. All primer sets tested were
purchased from Integrated DNA Technologies, Inc. (Coralville, IA) and are listed
in Table 5. Primer specificity was confirmed by real-time qPCR with genomic
DNA from overnight cultures. No cross-reactivity was found with any of the nontarget species tested.
Quantification of Bifidobacterium, Lactobacillus, and total bacteria was
achieved with real-time qPCR with ribosomal DNA-targeted genus-specific
primers using the CFX96™ Real-Time PCR Detection System (Bio-Rad Life
Science Research, Hercules, CA). Each plate experiment was replicated three
times and each reaction was carried out in triplicate in a volume of 15 µL using
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96-well optical-grade plates (MLL9601, Bio-Rad Life Science Research). Each
plate contained three no-template controls. The qPCR reactions were designed
as follows: 95ºC for 10 min (1X), 95ºC for 10 sec (40X), 57ºC for 30 sec (1X),
72ºC for 30 sec (1X), and 95ºC for 10 sec (1X). The Ct values were averaged for
each animal and primer set. Relative concentrations were calculated using the 2∆∆

CT method.61 FastStart DNA Master SYBR Green (Roche, Indianapolis) was

used for all qPCR reactions.
Statistical Analysis. Data were analyzed with SPSS 20.0.0 (SPSS Inc.,
Chicago, IL) and tested for normal distribution using the Shapiro-Wilk test. Nonparametric data were transformed and one-way analysis of variance (ANOVA)
test was performed. If ANOVA data were significant (p<.05), post hoc
comparisons were then made between individual groups using Tukey’s test.
Mean differences were considered significant at p<.05.
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CHAPTER 4
RESULTS
This study was conducted to determine how the consumption of prebiotics
and probiotics modified gut microbiota in obese ZDF rats and to describe the
bacterial profile in these animals associated with metabolic outcomes (i.e.,
hyperglycemia, adiposity, etc.). The experiments were designed to detect if soy
food supplemented with 2.5% fructooligosaccharides (FOS), Bifidobacterium
animalis (BIF), or Lactobacillus acidophilus (LAC) made a significant difference in
the number of microorganisms found in the gut; and, within those differences, if it
could be determined that either Lactobacillus or Bifidobacterium were selected
for.
Lactobacillus levels in obese female ZDF rats. Following three weeks
on experimental diets (Table 3), there were no significant differences in
Lactobacillus levels detected between diet groups F = 0.087, p=0.97; Figure 6).
To determine whether DNA levels of Lactobacillus (∆CT) were associated with
reported metabolic outcomes in female ZDF rats (Appendix C), Pearson’s
correlation coefficient (r) was used to assess the relationship with blood glucose
(Figure 7A) and body weight (Figure 7B). There was no significant correlation
observed between Lactobacillus levels and blood glucose (r=0.10, p=0.96) or
body weight (r = -0.24, p = 0.27).
Bifidobacterium levels in obese female ZDF rats. Unlike Lactobacillus,
there was a significant difference in Bifidobacterium content at termination
(F=9.46, p<0.001; Figure 8). More specifically, Bifidobacterium was lower in
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female obese ZDF rats fed BIF compared to LAC or FOS (p<0.05) (Figure 8).
There was also a significantly greater Bifidobacterium in FOS vs. CON fed rats
(data not shown; p<0.05). Pearson’s correlation coefficient (r) was then used to
determine if these differences in Bifidobacterium levels were associated with
changes in blood glucose (Figure 9A) or body weight (Figure 9B). There was no
significant correlation observed between Bifidobacterium levels and blood
glucose (r=0.017, p=0.87) or body weight (r=-0.04, p=0.95).
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CHAPTER 5
DISCUSSION & CONCLUSIONS
The purpose of this project was to quantitatively compare the probiotic and
total gut bacteria levels of female Zucker diabetic fatty (ZDF) rats whose soybased diet was supplemented with prebiotic FOS, probiotic B. animalis, or
probiotic L. acidophilus. The evidence in this study shows there were no
significant differences in Lactobacillus levels between any of the feeding groups
and the control group, supporting the conclusion that ingestion of any of the
tested supplemented food does not statistically modulate Lactobacillus numbers
in female ZDF rats. However, the rats from the Bifidobacterium and FOS feeding
groups had significantly higher colonic Bifidobacterium levels than the control
group from ingesting the supplemented food, indicating that the presence of the
probiotic Bifidobacterium animalis subspecies lactis and the prebiotic FOS
stimulated the growth of Bifidobacterium.
FOS supplementation of 0.25% FOS significantly stimulated intestinal
numbers of Lactobacillus over their control group and significantly lowered the
populations of the harmful bacteria E. coli and C. perfringens in a study with
broiler chickens.62 However, the 0.50% FOS feeding group gained less body
weight, had less Lactobacillus measured in their intestines, and more E. coli and
C. perfringens than the 0.25% FOS group, indicating that it was excessive to
supplement at the 0.50% FOS level.62 This may hold some significance in that
the preliminary study used 2.5% FOS supplement and the results of this study
increased but showed no significance.
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In most probiotic studies Lactobacillus counts are increased after probiotic
consumption. However, one probiotic study involving elderly volunteers reported
a decrease in the genus Lactobacillus bacteria in fecal counts after feeding a
probiotic cocktail of various Lactobacillus and Bifidobacterium species.63 The
researchers speculated the differences in results may have been caused by
differing isolation and identification techniques used.63 Another study involving
healthy, elderly volunteers yielded significantly higher numbers of bacteria from
the genus Bifidobacterium during the two-week synbiotic (containing
Bifidobacterium capsules and ingested oligofructose) feeding period and during
the three-week post-feeding period.64 The relative levels of colonic
Bifidobacterium of rats in the FOS feeding group differed from that of the control
and Bifidobacterium feeding groups, probably reflecting the prebiotic effect of
FOS, as it is known to stimulate Bifidobacterium numbers when administered as
a dietary supplement.65 B. animalis was detected in the bowel of rats
administered food supplemented with the prebiotic inulin compared to the control
group in another study.66 And in another, the mean level of Bifidobacte4rium was
between 2.2 and 3.5 times higher in short chain (sc)FOS-fed piglets than in
control animals.53
The results of this study are similar to the studies discussed above in that
Lactobacillus counts did not alter significantly, but Bifidobacterium counts did
increase significantly. They indicate that an interesting addition to our study
would have been to add two synbiotic feeding groups, Bifidobacterium/FOS and
Lactobacillus/FOS. Results from previous studies have shown that an easily
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accessed, preferred substrate increases the viability of the probiotic.51 In order
for all the rats to begin the experiment with a “sterile” gut, they could have been
given a round of antibiotics beforehand. Also, although Lactobacillus wis not
significantly higher in this study, it is trending higher. Therefore, it is possible that
with a higher n, the result may have become significant.
The hypothesis of the preliminary study was that the prebiotics or
probiotics added to the soy protein could have some effect on the intestinal
microflora. In the Bifidobacterium-fed group, lipid levels were higher than any of
the other feeding groups. It was concluded that the higher concentration of
probiotics likely produced SCFA and amino acids which were absorbed in the
colon and subsequently increased body lipids.12 It is likely that the Firmicutes in
the gut are responsible for this conversion.10
Using male rats in the study would provide another statistical group.
Further, use of a rat species that was not obese or prone to diabetes would likely
have resulted in a longer, more complete study of the effects of the different diet
groups since these rats developed diabetes so quickly and severely that the
study had to be stopped. In addition, it is possible that the wire-floor cages could
have been stressful for the animals as opposed to litter on a smooth cage floor,
causing the rats to eat more than they normally would have. This could alter the
ratios of the gut bacteria genera, thereby negatively skewing the results.62
A stool kit was used in DNA recovery from the colon samples for this
study. This method/kit may select for certain bacteria because not all bacteria
lyse equally well.67 Gram positive bacteria cell walls can be harder to penetrate
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than those of Gram negative bacteria.29,68 PCR reaction efficiencies may select
for bacteria with lower GC ratios than say, Bifidobacterium, due to various
melting and renaturation efficiencies.29 Even slight variations in DNA sequences
can cause non-detection of certain bacteria.68
Copy number variation is an application that requires accurate, absolute
quantification. This now can be accomplished using a recently developed
technology called droplet digital PCR that was not available at the time of data
collection for this research. This technology allows only about one target
molecule per reaction, and then hundreds or thousands of these reactions are
run in parallel.69 These reactions are not quantitative, but can determine the
proportion that contains template for the target in question, and precisely
determine copy number in the original sample.
Recommendations. There has been a vast amount of research done in
the field of prebiotics and probiotics demonstrating health improvements, but
there is a lack of cause and effect answers. Future research needs to link
prebiotic and/or probiotic modifications with precise physiological actions leading
to specific health benefits. The colonic measurements performed in this study
cannot be indicative of prebiotic and probiotic feeding effects on the small
intestinal ecosystem as a major target of viable probiotic strains. Furthermore,
the small intestine is the most important site of energy absorption. Therefore, the
results of this study cannot lead to any suppositions toward understanding the
relationship between obesity and the microbiome. After recent discoveries of this
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relationship, modern research likely will focus heavily on this aspect of prebiotic
and probiotic supplementation.
Metagenomics approaches will provide valuable genetic information
regarding gastrointestinal bacteria. For example, the recent Human Microbiome
Project directed by the National Institutes of Health (NIH) is sequencing and
analyzing the genomes of about 600 GI bacteria. This study will examine the
roles of microbial communities in the gut as well as bacteria from other human
body sites, how they all interact with each other, and the relationship between
disease and changes in the human microbiome.70-72 This will give us a global
view of the potential beneficial effects of probiotic and other commensal intestinal
bacteria.
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TABLES

Table 1. Summary of some benefits of probiotics administration to
humans
Decrease incidence of dental caries 28
Attenuate lactose intolerance symptoms 28
Alleviates mucosal inflammation due to H. pylori infection 73
Reduce intestinal pathogens:
reduce intestinal permeability by modifying epithelial barrier function 17
inhibit the growth and survival of pathogenic bacteria 4,10,17,31
interrupt bound pathogenic bacteria 17
promote defense barrier functions on the gut epithelial cells 74
interrupt DNA, RNA, or protein synthesis/structure, or penetrate the inner
membrane of gram-positive pathogens 17
produce high levels of lactic acid and SCFAs to the detriment of pHsensitive pathogens 10,20
increase intestinal motility, absorption, defecation frequency, lipid and
carbohydrate metabolism, mucus production, and blood flow to the
large intestine from production of SCFAs 35,44,45
modify epithelial barrier function by reducing intestinal permeability 17
Improve bowel function:
produce digestive enzymes 51
reduce symptoms of irritable bowel syndrome (IBS) 28,30
shorten duration of infant infectious diarrhea 28
reduce symptoms of diarrhea (particularly antibiotic-associated) 17,31
reduce symptoms of ulcerative colitis 31,32
provide energy for colonocytes 31,33
lower the pH of the colon to maintain integrity of the mucosa 41,75
Immune system benefits:
increase intestinal immune response 18
combat allergies 35,40,76
improve atopic dermatitis in children 2 years and over 77
affect development and function of dendritic cells 41
raise sIgA secretion levels into the luminal mucous layer 17
repress rotaviruses 51
Reduce respiratory infections 28
Prevent urinary tract and vaginal infections 78
Treat infections during pregnancy 78
Retard carcinogenesis process 44
Lower hypertension 79
Obesity link 9,11
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Table 2. Examples of common probiotics, prebiotics, and synbiotics1
Probiotics
Lactobacillus
L. acidophilus
L. casei
L. delbrueckii subsp. bulgaricus
L. reuteri
L. brevis
L. cellobiosus
L. curvatus
L. fermentum
L. plantarum
Gram-positive cocci
Lactococcus lactis subsp. cremoris
Streptococcus salivarius subsp. thermophilus
Enterococcus faecium
Streptococcus diacetylactis
Streptococcus intermedius
Bifidobacterium
B. bifidum
B. adolescentis
B. animalis
B. infantis
B. longum
B. thermophilum
Prebiotics
FOS (e.g., oligofructose and neosugar)
Inulin
GOS
Lactulose
Lactitol
Synbiotics
Bifidobacterium + FOS
Lactobacillus + lactitol
Bifidobacterium + GOS
1

Some still under evaluation.
FOS, fructooligosaccharides; GOS, galactooligosaccharides. 51
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Table 3. Composition of experimental diets1
Ingredient2

CON

FOS3

BIF4

LAC5

Soy6
Sucrose
Starch
Functional
Soybean oil
Lard
Fiber
Vitamins
Minerals
Cysteine
Choline
BTHQ

200
250
179
0
70
200
50
10
35
3
2.5
0.014

200
250
154
25
70
200
50
10
35
3
2.5
0.014

200
250
154
25
70
200
50
10
35
3
2.5
0.014

200
250
154
25
70
200
50
10
35
3
2.5
0.014

1

Energy Density: 4.85 kcal/g-1 (Protein 17%, Carbohydrate 33%, and Fat 50% of

total kcal)
2

ICN Biomedicals, Costa Mesa, CA

3

FOS diet contains 2.5% fructooligosaccharide

4

Bifidobacterium animalis subspecies lactis (1.0 x 1010 cfu g-1, Lyoferm, Inc.,

Indianapolis)
5

Lactobacillus acidophilus (1.0 x 109 cfu g-1, Lyoferm, Inc., Indianapolis)

6

Supro® Soy Protein Isolate, Solae LLC, St. Louis, MO
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Table 4. Bacterial strains used as controls during the primer
optimization
Bacteria

Gram-stain

Lactobacillus acidophilus

+

Bifidobacterium infantis

+

Bacillus cereus

+

Staphylococcus aureus

+

Enterococcus faecalis

+

Enterobacter aerogenes

–

Proteus vulgaris

–

Salmonella typhimurium

–

Escherichia coli

–
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Table 5. qPCR primers tested for Bifidobacterium, Lactobacillus, and total bacteria concentration
Primer

Target Genera/Group

Lact-F

Lactobacillus (Leuconostoc,
Pediococcus, Aerococcus, &
Weissella, but not Enterococcus/
Streptococcus

Annealing
Temp (ºC)

Sequence 5'→3'

52.8

CACCGCTACACATGGAG

52.7

AGCAGTAGGGAATCTTCCA

53.7

GGTGTTCTTCCCGATATCTACA

55.6

CTCCTGGAAACGGGTGG

57.8

CGTYTCBCAGCCGGAYAAC

recA-R

58.5

CCARVGCRCCGGTCATC

P338FGC

61.3

ACTCCTACGGGAGGCAGCAG

58.7

ATTACCGCGGCTGCTGG

54.3

AGAGTTTGATCMTGGCTCAG

65.1

ACCGCGGCKGCTGG

Lact-R
g-Bifid-F

recA-F
Bifidobacterium

Domain Bacteria
P518R
8F
Domain Bacteria
529R
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FIGURES

Figure 1. Obesity trends among U.S. adults. The CDC’s Behavioral Risk
Factor Surveillance System reports indicate obesity trends according to BMI
calculated from self-reported telephone interviews with U.S. adults in 1990, 2000,
and 2010. Obesity is indicated by a BMI of ≥30 (e.g., about 30 lbs. overweight
for 5’4” person) 1. In 1990, no state had a prevalence of obesity ≥15%. However,
by 2012, several states had a prevalence ≥30%.
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Figure 2. The gastrointestinal tract, illustrating bacterial quantities (each
symbol ≈ 10-fold cells. Aerobic (red) vs. anaerobic (blue), and Gram-negative (–)
vs. Gram positive (+).4,21
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Figure 3. Microbiota transplantation. These experiments demonstrate that
ob/ob microbiota harvest more dietary energy than their wild-type littermates. (a)
Fecal gross energy content of lean (+/+, ob/+; n=9) vs. obese (ob/ob; n=13)
C57BL/6J mice demonstrates that obese mice have significantly less energy that
remains in their feces than lean wild-type mice. (b) Germ-free wild-type mice
colonized with microbiota from the cecum of obese (ob/ob) donor mice displayed
a significantly higher percentage increase in body fat percentage over wild-type
mice colonized from lean (+/+) donors. Figure adapted Turnbaugh et al. (2006) 9.
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Figure 4. Relative abundance of Firmicutes and Bacteroidetes. In a one-year
human study, the relative abundance of Firmicutes and Bacteroidetes. Sample
average values at each time point (n = 11 or 12/time point). Lean controls
averaged one year apart. Figure adapted Ley et al. (2006)11.
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Figure 5. Bacteroidetes relative change in abundance. The Bacteroidetes
group increased in abundance according to percentage of body weight lost in a
study of a carbohydrate-restricted diet group with subjects who experienced
greater than 2% body weight loss and subjects from a fat-restricted diet group
who lost greater than 6% body weight. Figure adapted Ley et al. (2006)11.
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Figure 6. The abundance levels of Lactobacillus in DNA extracted from
colon of female ZDF rats. Data values represent mean fold change calculated
using the 2-ΔΔCT method61. Data were analyzed using ΔCt values for each sample
(Ct Lactobacillus n – Ct Total Bacteria n), n = 24. The data were tested for
normality (Kolmogorov-Smirnov, p=0.13 and Shapiro-Wilk, p=0.18) and analyzed
using a one-way analysis of variance (ANOVA). There was no significant
difference in abundance levels of Lactobacillus (F=0.087, p=0.97).
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A

B

Figure 7. Relationship between Lactobacillus levels in colon and blood
glucose and body weight in female ZDF rats. Scatter plot analysis of relative
Lactobacillus levels (fold change) and (A) fasting blood glucose concentration
(mg/dl), and (B) body weight (grams). Pearson’s correlation coefficients (r) were
r=0.10 (p=0.96) and r=-0.24 (p=0.27) for glucose and body weight, respectively.
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Figure 8. The abundance levels of Bifidobacterium in DNA extracted from
colon of female ZDF rats. Data values represent mean fold change calculated
using the 2-ΔΔCT method 61. Data were analyzed using ΔCT values for each sample
(CT Bifidobacterium n – CT Total Bacteria n), n = 24. The data were tested for
normality (Kolmogorov-Smirnov, p=0.13 and Shapiro-Wilk, p=0.18) and analyzed
using a one-way analysis of variance (ANOVA). There was a significant
difference in abundance levels of Bifidobacterium among groups (F= 9.46,
p<0.001). Multiple comparisons were then made using Tukey’s HSD test.
Significant differences (at p<0.05) between means were indicated by different
letters.

41

`
A

B

Figure 9. Relationship between Bifidobacterium levels in colon and blood
glucose and body weight in female ZDF rats. Scatter plots analysis of relative
Bifidobacterium levels (fold change) and (A) fasting blood glucose concentration
(mg/dl), and (B) body weight (grams). Pearson’s correlation coefficients were
0.017 (p=0.87) and -0.04 (p=0.95) for glucose and body weight, respectively.
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APPENDIX A
Taxonomic Description of Genera Lactobacillus and Bifidobacterium
BACTERIA

Firmicutes

Actinobacteria

Bacilli

Actinobacteria

Actinobacteridae
s

Bifidobacteriumles

Lactobacillales

Bifidobacteriumceae

Lactobacillacea
e
Lactobacillus
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APPENDIX B

qPCR primer tests for Bifidobacterium, Lactobacillus, and total
bacteria

Bifidobacterium. Graphical representation of real-time qPCR results comparing
primer sets to detect genus Bifidobacterium, tested by using DNA of control
bacteria, Lactobacillus infantis, and Bifidobacterium animalis subspecies lactis.

Lactobacillus. Graphical representation of real-time qPCR results for the primer
set Lact to detect genus Lactobacillus, tested using DNA of control bacteria,
Lactobacillus infantis, and Bifidobacterium animalis subspecies lactis.

Total Bacteria. Graphical representation of real-time qPCR results comparing
primer sets to detect total bacteria.
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APPENDIX C
Measurements of ZDF rats subjected to high-fat diets containing prebiotics
and probiotic for three weeks

CON

FOS

BIF

LAC

Total food
intake (g)

391.7±8.4

410.9±8.7

394.8±10.0

402.1±14.1

Final blood
glucose (mg/dl)

270.0±34.6

241.2±44.1

306.0±35.9

320.0±9.5

Body weight
gain (g)

118.2±4.0

114.8±6.1

113.7±4.6

114.8±3.7

Final body
lipid (%)

48.2±2.7

45.9±1.9

59.5±3.1

46.1±3.7

Data represent treatment means ± standard error. Letters indicate significant difference
between groups as determined from one-way ANOVA and Tukey HSD multiple
comparison.
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